Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase EARLY_PHASE1 1Phase 2 1Phase 1/2 1

Status

Completed 2Terminated 1Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 4Observational 2

Sponsor

Cancer Type

CNS 6

Conditions

Breast Neoplasms 3137Neoplasms 2474Carcinoma, Non-Small-Cell Lung 1883Prostatic Neoplasms 1641Colorectal Neoplasms 1432Lung Neoplasms 1308Multiple Myeloma 937Neoplasm Metastasis 926Leukemia, Myeloid, Acute 885Pancreatic Neoplasms 860Ovarian Neoplasms 814Melanoma 791Carcinoma, Hepatocellular 743Stomach Neoplasms 647Recurrence 640Brain Neoplasms 640Squamous Cell Carcinoma of Head and Neck 638Head and Neck Neoplasms 609Glioblastoma 573Uterine Cervical Neoplasms 549Lymphoma 549Triple Negative Breast Neoplasms 514Precursor Cell Lymphoblastic Leukemia-Lymphoma 511Carcinoma, Renal Cell 504Endometrial Neoplasms 467Hematologic Neoplasms 464Urinary Bladder Neoplasms 462Colonic Neoplasms 447Lymphoma, Non-Hodgkin 437Sarcoma 436

Interventions

daratumumab 1Watchful Waiting 1Atorvastatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Hemangioma, Cavernous, Central Nervous System × 1 year × Clear all
NCT02603328 2025-08-22

AT CASH EPOC

University of Chicago

Phase 1/2 Completed
80 enrolled 19 charts
CNS

Hemangioma, Cavernous, Central Nervous System

NCT04467489 2025-08-11

Biomarkers of CASH

University of Chicago

Active not recruiting
1,040 enrolled
CNS

Hemangioma, Cavernous, Hemangioma, Cavernous, Central Nervous System

NCT05085561 2025-08-06

SYCAMORE

Recursion Pharmaceuticals Inc.

Phase 2 Completed
62 enrolled
CNS

Hemangioma, Cavernous, Central Nervous System

NCT06214767 2025-07-30

Study on Treatment Decision-Making and Prognostic Follow-Up for Untreated Cerebral Cavernous Malformations

Beijing Tiantan Hospital

Recruiting
1,200 enrolled
CNS

Hemangioma, Cavernous, Central Nervous System

NCT07026604 2025-06-18

CCM-DS01

Beijing Tiantan Hospital

Phase EARLY_PHASE1 Not yet recruiting
10 enrolled
CNS

Hemangioma, Cavernous, Central Nervous System

NCT05298709 2025-06-11

Functional Magnetic Resonance Imaging (fMRI) Vascular Reactivity in Cerebral Cavernous Malformations (CCM)

University of New Mexico

Phase NA Terminated
5 enrolled
CNS

Hemangioma, Cavernous, Central Nervous System

Data powered by HemOnc (CC BY 4.0) Colophon âš¡